These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27460206)

  • 1. Therapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions.
    Rodgers KR; Chou RC
    Biotechnol Adv; 2016 Nov; 34(6):1149-1158. PubMed ID: 27460206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies as innovative therapeutics.
    Reichert JM
    Curr Pharm Biotechnol; 2008 Dec; 9(6):423-30. PubMed ID: 19075682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic antibodies and antibody fusion proteins.
    Rohrbach P; Broders O; Toleikis L; Dübel S
    Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of antibodies and chimeric molecules for cancer immunotherapy.
    Waldmann TA; Morris JC
    Adv Immunol; 2006; 90():83-131. PubMed ID: 16730262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic antibodies: magic bullets hit the target.
    Gura T
    Nature; 2002 Jun; 417(6889):584-6. PubMed ID: 12050630
    [No Abstract]   [Full Text] [Related]  

  • 6. Current and experimental antibody-based therapeutics: insights, breakthroughs, setbacks and future directions.
    Murad JP; Lin OA; Espinosa EV; Khasawneh FT
    Curr Mol Med; 2013 Jan; 13(1):165-78. PubMed ID: 22834842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic antibodies and related products: choosing the right structure for success].
    Beck A; Wagner-Rousset E; Wurch T; Corvaia N
    Med Sci (Paris); 2009 Dec; 25(12):1024-32. PubMed ID: 20035674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antibodies.
    Billetta R; Lobuglio AF
    Int Rev Immunol; 1993; 10(2-3):165-76. PubMed ID: 8360583
    [No Abstract]   [Full Text] [Related]  

  • 10. New monoclonal antibodies in renal transplantation.
    Vincenti F
    Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Introduction to "Recent Trends in the Biotechnology Industry: Development and Manufacturing of Recombinant Antibodies and Proteins".
    Pohlscheidt M; Kiss R; Gottschalk U
    Adv Biochem Eng Biotechnol; 2018; 165():1-8. PubMed ID: 29748871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological therapies for rheumatoid arthritis: progress to date.
    Malviya G; Salemi S; Laganà B; Diamanti AP; D'Amelio R; Signore A
    BioDrugs; 2013 Aug; 27(4):329-45. PubMed ID: 23558378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
    Khalil DN; Smith EL; Brentjens RJ; Wolchok JD
    Nat Rev Clin Oncol; 2016 May; 13(5):273-90. PubMed ID: 26977780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies come back from the brink.
    Holliger P; Hoogenboom H
    Nat Biotechnol; 1998 Nov; 16(11):1015-6. PubMed ID: 9831027
    [No Abstract]   [Full Text] [Related]  

  • 15. Human monoclonal antibodies from transgenic mice.
    Lonberg N
    Handb Exp Pharmacol; 2008; 181(181):69-97. PubMed ID: 18071942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond.
    Bello C; Sotomayor EM
    Hematology Am Soc Hematol Educ Program; 2007; ():233-42. PubMed ID: 18024635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downstream processing of monoclonal antibodies--application of platform approaches.
    Shukla AA; Hubbard B; Tressel T; Guhan S; Low D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):28-39. PubMed ID: 17046339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry hyphenation.
    Goyon A; D'Atri V; Colas O; Fekete S; Beck A; Guillarme D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Oct; 1065-1066():35-43. PubMed ID: 28946123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R
    Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
    [No Abstract]   [Full Text] [Related]  

  • 20. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM; Boado RJ
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.